suresh ramalingam: osimertinib vs comparator egfr-tki 1st-line in egfrm advanced nsclc (flaura)
Published 4 years ago • 98 plays • Length 8:55Download video MP4
Download video MP3
Similar videos
-
6:21
flaura study of osimertinib versus tki for 1st line nsclc
-
8:44
flaura final analysis: osimertinib for first-line egfrm nsclc
-
2:20
osimertinib in advanced non–small-cell lung cancer
-
1:24
suresh ramalingam, md, fasco, shares results from the flaura trial presented at esmo 2019
-
2:04
dr. suresh ramalingam on frontline osimertinib data in egfr nsclc
-
0:53
ramalingam compares third generation egfr tki osimertinib to older agents in nsclc
-
6:50
osimertinib: a potential new standard of care for advanced egfr-mutated nsclc | suresh ramalingam
-
2:34
dr. ramalingam on flaura findings in egfr-mutant nsclc
-
35:08
cancer survivor story: my successful targeted therapy treatment | ashley's story (2 of 3)
-
5:32
introduction to egfr inhibitors
-
4:44
understanding non-small cell lung cancer
-
2:20
osimertinib with chemotherapy in egfr-mutated nsclc | nejm
-
2:20
adjuvant osimertinib in resected egfrm nsclc: the os data from the adaura trial
-
1:50
researcher comment: positive os data for osimertinib in flaura trial | suresh ramalingam
-
1:05
dr. ramalingam on the activity of osimertinib combinations in nsclc
-
1:40
dr. ramalingam on the role of osimertinib in egfr t790m-positive advanced nsclc
-
1:08
dr. ramalingam on the os results of the flaura trial in egfr-mutant nsclc
-
1:45
dr. ramalingam on the use of osimertinib in clinical trial and real-world settings
-
2:09
dr. ramalingam on flaura trial results in egfr-mutant nsclc
-
1:19
dr. ramalingam on the significance of the flaura trial in nsclc
-
5:42
osimertinib and the flaura trial
-
0:47
suresh ramalingam, md, on how the flaura trial may impact care for egfr-mutated nsclc